Astellas Announces FDA Update on the FORTIS Clinical Trial of AT845 in Adults with Late-Onset Pompe Disease

Astellas Announces FDA Update on the FORTIS Clinical Trial of AT845 in Adults with Late-Onset Pompe Disease

TOKYO, June 26, 2022 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced that the US Food and Drug Administration (FDA) has placed a clinical hold on the FORTIS Phase 1/2 trial following the occurrence of a serious adverse event (SAE) of peripheral sensory neuropathy in one of the … Read more

DEM BioPharma Launches with $70 Million Financing

DEM BioPharma Launches with  Million Financing

CAMBRIDGE, Mass.–(BUSINESS WIRE)– DEM BioPharma, Inc. (DEM Bio), an immuno-oncology company developing therapies that target novel innate immune system checkpoints to eliminate cancer, today announced its initial $70 million financing led by founding investor Longwood Fund and Alta Partners, with additional participation from Insight Partners, Pfizer Ventures, Astellas Venture Management, Emerson Collective, UTokyo Innovation Platform … Read more

Opus Genetics Appoints Ben Yerxa, Ph.D., as Permanent Chief Executive Officer

Opus Genetics Appoints Ben Yerxa, Ph.D., as Permanent Chief Executive Officer

Industry veteran and experienced CEO will continue to lead the company as its AAV-based gene therapies for inherited retinal diseases approach the clinic RESEARCH TRIANGLE PARK, NC, June 21, 2022 (GLOBE NEWSWIRE) — Opus Genetics, a patient-first gene therapy company developing treatments for inherited retinal diseases, today announced the appointment of Ben Yerxa, Ph.D., as … Read more

Global Roundup: Olink Publishes Updated Genetic Atlas of the Plasma Proteome

Global Roundup: Olink Publishes Updated Genetic Atlas of the Plasma Proteome

Sweden-based Olink Holding AB published an article describing the early findings of proteomics research conducted by the UK Biobank Pharma Proteomics Project. The article, “Genetic regulation of the human plasma proteome in 54,306 UK Biobank participants,” was published online on the bioRxiv preprint server. The UK Biobank is a biomedical database and research resource containing … Read more

Rain Targets Normal p53 Expression with Possible Pan-Cancer Therapeutic

Rain Targets Normal p53 Expression with Possible Pan-Cancer Therapeutic

Rather than target mutated p53, Rain Therapeutics is looking at normal p53 expression as part of its novel mouse double minute 2 homolog (MDM2) inhibitor therapy. In the coming 12 months, Rain expects to have an interim readout for a Phase II study of its liposarcoma therapy, called milademetan (Rain-32), and a pivotal readout for … Read more